34 results about "Brown adipose cell" patented technology

Methods and devices are provided for activating brown adipose tissue with targeted substance delivery. Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss and / or improved metabolic function. In one embodiment, a chemical configured to stimulate nerves that activate the BAT and / or to stimulate brown adipocytes directly can be delivered to a patient, thereby increasing thermogenesis in the BAT and inducing weight loss and / or improved metabolic function through energy expenditure. The chemical can be delivered to the patient locally and / or systemically to stimulate the nerves and / or the brown adipocytes.

Brown adipose tissue (“BAT”) progenitor cells and methods for identifying BAT progenitor cells in a population of cells are provided. Methods are also provided for inducing differentiation of BAT progenitor cells into differentiated brown adipocytes, inducing expression or increased activity levels of BAT uncoupling protein-1 (“UCP1”), and for identifying agents capable of inducing differentiation of BAT progenitor cells into brown adipocytes and / or inducing expression or increased activity levels of UCP1. Differentiated brown adipocytes and agents and methods for inducing differentiation of BAT progenitor cells can be used for treatment of, or the making of medicaments for the treatment of, metabolic diseases or conditions in a patient such as obesity, overweight, impaired glucose tolerance, insulin-resistance, type 2 diabetes, dyslipidemia, hypertension, cardiovascular diseases, metabolic syndrome, and the like. Differentiated brown adipocytes and agents and methods for inducing differentiation of BAT progenitor cells can be used for prevention of hypothermia.

The present invention addresses the problem of providing: a brown adipocyte; a method for preparing the brown adipocyte; a transplantation material containing a brown adipocyte; a prophylactic or therapeutic agent for various diseases and conditions, which contains a brown adipocyte; and a use. As a means for solving the problem, a method for preparing a brown adipocyte is provided, said method being characterized by comprising culturing a differentiated somatic cell from a mammal in a culture medium in the presence of at least one compound selected from the group consisting of (1) a TGFbeta / SMAD pathway inhibitor, (2) a casein kinase 1 inhibitor, (3) a cAMP inducer and (4) an MEK / ERK pathway inhibitor to convert the somatic cell into a brown adipocyte.

A method for converting animal cells into brown adipose tissue cells is provided that includes transforming the animal cells using an expression vector. The expression vector includes a nucleotide sequence encoding HB-EGF operatively linked to a promoter and a nucleotide sequence encoding ADAM 12 operatively linked to a promoter. Converting animal cells to brown adipose tissue cells can be used to treat obesity or to treat cancer by converting target cells to brown adipose tissue cells.

Methods of generating functional human brown adipocytes, comprising exposing human stem cells, progenitor cells, or white adipocytes to culture with an differentiation cocktail that comprises one or more browning agents (e.g., one or more macromolecular crowders), and optionally one or more adipogenic agents, are described, as are populations of human brown adipocytes generated by the methods, and uses for the populations. Methods of generating functional human brown adipocytes in an individual, such as by administering a pharmaceutical composition comprising an differentiation cocktail, are also described.

Provided are a method of producing brown adipocytes from pluripotent stem cells, a method of producing cell aggregates as an intermediate product thereof, pluripotent stem cell-derived cell aggregates and pluripotent stem cell-derived brown adipocytes produced by these methods, and cell therapy using the pluripotent stem cell-derived brown adipocytes. In the method of producing brown adipocytes from pluripotent stem cells, cell aggregates are produced from pluripotent stem cells by a method including the step (A), and brown adipocytes are prepared from the cell aggregates by a method including the step (B). The step (A) is a step of producing cell aggregates by non-adhesive culture of pluripotent stem cells in serum-free environment in the presence of a hematopoietic cytokine, and the step (B) is a step of producing brown adipocytes by adhesion culture of the cell aggregates in the presence of a hematopoietic cytokine.

The invention provides a method for treatment of liver cancer in a subject, wherein the method includes that brown adipose cells or compositions thereof are applied to the subject, a drug delivery route of the brown adipose cells is carried out through intratumoral, intraarterial, intravenous, intrapleural, intracystic, intracavitary or abdominal injection or oral administration, and the drug delivery route of the brown adipose cells comprises the step of injecting a brown adipose cell suspension to the subject. The invention also provides a method for constructing a mice liver cancer model, wherein the method comprises the step of reducing or excising brown adipose tissues in mice bodies or reducing brown adipose cells in the mice bodies; preferably, the method comprises the step of carrying out surgical excision or partial excision of the brown adipose tissues in the mice bodies; the invention also provides a method for inhibition of proliferation or metastasis of liver cancer cellsin vivo or in vitro. Inhibition of the liver cancer cells or reduction of metastasis of the liver cancer cells are achieved by contact with the liver cancer cells in vivo or in vitro or mixing with the brown adipose cells.

The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-α (Pgd1α) and / or uncoupling protein 1 (Thermogenin / Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.